Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy

NCT01056276 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

59

Enrollment

OTHER

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Bendamustine
DRUG: Bortezomib
DRUG: Dexamethasone

Sponsor

SCRI Development Innovations, LLC

Collaborators

[object Object]
[object Object]